[Permanent interstitial brachytherapy (seeds) for patients with primary localized prostate cancer: analysis of 100 patients].
BACKGROUND
The aim of this retrospective study was to evaluate late toxicity and biochemical disease-free survival of patients with primary localised prostate cancer, who had been treated with permanent seed implantation at the radiotherapy department of the Medical University of Vienna.


METHODS
Between 08/1999 and 11/2006 100 patients were treated with ultrasound guided transperineal seed implantation (94 patients with Iodine and 6 patients with Palladium). 53 patients received additional hormone therapy. According to T-stage, Gleason Score and PSA, patients were divided into three risk groups (low, intermediate and high risk). Late gastrointestinal and genitourinary side effects and biochemical disease-free survival were evaluated.


RESULTS
The patients were followed up at a median time of 28 months (3-88 months). The median patient age was 67.5 years (47-79 years). The distribution of low, intermediate and high risk group patients was 63%, 35% and 2%. The 2-year actuarial rates of late Grade > or =2 gastrointestinal and genitourinary side effects were 5% and 65%. The 2-year biochemical disease-free survival rate was 88% (all patients), 90% (low risk) and 88% (intermediate risk), respectively. Multivariate analysis demonstrated T-stage (p = 0.03), PSA (p = 0.02) and patient age (p = 0.02) to be significant factors influencing biochemical disease-free survival.


CONCLUSIONS
Ultrasound guided transperineal seed implantation in patients with low-risk prostate cancer is an additional treatment option showing promising results.
Goldner
Gregor
G
Klinik für Strahlentherapie, Medizinische Universität Wien, AKH, Wien, Austria. gregor.goldner@akhwien.at
Ozdemiroglu
Nevin
N
Wachter
Stefan
S
Hendrik Knocke
Thomas
T
Pötter
Richard
R
D000368:Aged; D001317:Austria / Q000453:epidemiology; D001918:Brachytherapy / Q000295:instrumentation / Q000379:methods / Q000401:mortality*; D015897:Comorbidity; D018572:Disease-Free Survival; D005767:Gastrointestinal Diseases / Q000453:epidemiology*; D006801:Humans; D008297:Male; D052801:Male Urogenital Diseases / Q000453:epidemiology*; D008875:Middle Aged; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000453:epidemiology*; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome